Catalent Expands its Plant-Based Consumer Health Softgel Capabilities
The expansion included adding new softgel encapsulation lines at its Strathroy, Canada and Sorocaba, Brazil sites for Catalent’s Vegicaps plant-based capsule and its CosmoPod twist-off capsule technologies.
Catalent announced on June 30, 2020 that it has completed a $3.2-million expansion program at its consumer health manufacturing facilities in Strathroy, Canada and Sorocaba, Brazil.
According to a company press release, the expansion included adding new softgel encapsulation lines at each site for Catalent’s Vegicaps plant-based capsule and its CosmoPod twist-off capsule technologies. Now, the company will be able to support its customers in North and Latin America looking to develop all-natural and plant-based vitamins, minerals, and supplements.
“We have seen increased consumer demand for greater product choice, with sales of plant-based softgel technologies growing by more than 25% globally in recent years. Additionally, Brazil has grown to become the world’s fourth-largest market for beauty care products,” said Dr. Aris Gennadios, president, Softgel and Oral Technologies, Catalent, in the press release. “While we have been supplying the North and Latin American markets with plant-based softgel capsules from our manufacturing sites in Italy and Germany, this investment allows us to provide local supply solutions to markets that complement existing capabilities in Europe.”
Source: Catalent
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
